Still ordering hydralazine? 🤔
Beyond case reports, this large cohort compares hydralazine vs ACEi/ARB to estimate real-world vasculitis risk, will this 📉 bias & clarify the answer
Read more 👇
pubmed.ncbi.nlm.nih....
#TenPostNephJC #NephJC
#NephSky #MedSky
Nursing Home-based dialysis is growing quickly and now forms a significant part of home hemodialysis. Further research is necessary on hospitalization, mortality, functional status, and return-to-home outcomes specific to each type. kidney.pub/JASN1109
Late-breaking #Lancet SCOUT RCT results at #ESCMIDGlobal2026:
💊 Day 7 clinical resolution
• Nitrofurantoin: 74%
• Pivmecillinam: 70%
• Fosfomycin (2 doses): 67%
• Fosfomycin (single dose): 59%
🔑 single-dose fosfomycin underperforms vs standard short-course regimens
Check out the VA on hydralazine and population vasculitis risk by Dr. Divya Bajpai #NephSky
www.nephjc.com/news/2026/4/hydralazine-anca-va
This is for a patient with Acinetobacter Baumanii peritonitis. Planning to change the transfer set and titanium connector as well
Quick question - if I want to give Cefoperazone-Sulbactam for IP antibiotics for Automated PD with 10L exchanges can I use the Cefoperazone data in ISPD guidelines ie 500mg/L loading with 125mg/L for maintainence or is that overkill? #AskRenal
Thanks . Had discussed 3 weeks IP with patient earlier and was wondering if that would be adequate
But fluid has cleared up significantly and cell counts down. My next question is how long I need to continue antibiotics for
Gram negative organism unfortunately - garden variety E Coli - non ESBL sensitive to Ceftazidime and most other antibiotics
Patient is slowly improving. Effluent looks clearer after a day of IP Ceftazidime + IP Cefazolin both his night cycle and during the Icodextrin day dwell. Waiting for the counts to confirm improvement
I am hoping I don't have to remove it as my only dialysis access would be a femoral vein (transhepatic is out of the picture due to the peritonitis)
The gastro says this is a common finding on CT scan post polypectomy and that is why clips are used and that since there is no inflammatory reaction it's unlikely to be a full blown perf
🎥 Explore the onconephrology case presentation series on the ISN Academy, in collaboration with ASON.
Tackle real-world challenges in cancer & kidney care.
📌 Latest case: AKI post haematopoietic stem cell transplantation (HSCT)
👉https://academy.theisn.org/onconephrologycases
Removal would be simple because I inserted the catheter
On fluconazole antifungal - considered an echinocandin at the outset considering the microperf
Should I remove the tenckhoff and reinsert later or try intraperitoneal antibiotics first?
CT scan shows multiple surgical clips in ascending colon, hepatic flexure and splenic flexure and distal transverse colon. There is extraluminal air surrounding hepatic flexure
Murky light brown PD fluid in bag
Patient on Automated PD presents with hypotension, abdominal pain , fever for 2 days. Symptoms developed after colonoscopy with polypectomy.
Pseudoaneurysm of dialysis fistula with impending rupture
#POCUS
Awesome #nephmadness write up about resistant #hypertension renal denervation vs. novel drugs @stephanietr612.bsky.social @jordybc.bsky.social and visual abstracts @nephroseeker.medsky.social …And troubling AI-generated kidney art with tablet-shaped electroshockers i@littlebiggloms.bsky.social
Dear ASDIN Members: Due to the importance of this message below to our field, ASDIN is sharing the Medtronic media statement with our membership. ASDIN will continue to advocate on behalf of our members and will work with other providers to continue availability of endoAVF options for patients. Medtronic Statement Medtronic has made the decision to discontinue offering the Ellipsys ™ Vascular Access System for arteriovenous fistula (AVF) creation in all geographies. In a commitment to our customers, we will ensure they have up to 12 months of supply and up to six months of field, clinical, and cannulation support and will work closely with stakeholders to transition to alternative fistula creation solutions over the coming months. This decision will not limit patient or physician options for fistula creation. As the current standard of care, surgical fistula creation remains an option for any patient who would be a candidate for the Ellipsys system and an alternative endovascular fistula creation technology is commercially available in the U.S. and other regions. Medtronic remains committed to the arteriovenous market, focusing on effective fistula maintenance with our IN.PACTT™ AV drug-coated balloon and the Fortrex ™ HP PTA balloon catheter. While this was a difficult decision, this strategic shift will enable us to prioritize our resources towards fostering innovation and developing new therapies where we can have the most significant impact. This decision is aligned to Medtronic's active portfolio management work, an important lever to delivering on the company's long-term strategic and financial objectives.
Medtronic pulling out of the endovascular fistula creation market. Wow.
This is from the American Society of Diagnostic and Interventional Nephrology. And can't find this information on the medtronic website or with google. That may be a me problem though.
Throwback to the #NephMadness percutaneous AVF discussion
ajkdblog.org/2020/03/13/n...
TCC at right PUJ causing right obstructive uropathy. Growing into proximal ureter #POCUS
TCC at the PUJ of the Right Kidney causing obstructive uropathy
Can subcut Rituximab be used in Lupus Nephritis? Would save a lot of time
Amazing that people think anyone misses X as a site for professional development. To me personally X will remain just a place to catch up on news and occasionally criticize politicians in my country
A Kaplan-Meier survival curve showing cumulative survival over a 28-day in-hospital stay period for four groups: "Vaccinated without AKI" (blue line), "Vaccinated with AKI" (red line), "Not Vaccinated without AKI" (green line), and "Not Vaccinated with AKI" (orange line). The x-axis represents in-hospital stay in days, and the y-axis represents cumulative survival. The survival rate decreases more sharply in the "Not Vaccinated with AKI" group, followed by the "Vaccinated with AKI" group. The "Vaccinated without AKI" group has the highest survival, followed by the "Not Vaccinated without AKI" group. A log-rank test shows a p-value of 0.026, indicating a statistically significant difference in survival between the groups.
Research shows that COVID-19 vaccination reduces the risk of AKI and 28-day mortality in hospitalized patients with severe COVID-19. 📉💉
Learn more about the protective effects of vaccination! @Froylan_EndoMD @cjkhd.bsky.social @csnscn.bsky.social #COVID19 #Vaccination #KidneyHealth #CJKHD
